Medicare Rx Plan Negotiations Will Avert Drug Industry "Windfall" – PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
The industry group disputes predictions that the 2006 transfer of "dual eligibles" to Medicare will significantly benefit drug makers as Medicaid "best price" requirements no longer apply. However, states may lose price negotiating power, PhRMA says.